Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.60 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.60 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.60 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.60 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | THPO | P40225 | 1/20 | 0.60 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.60 |
| ▸ | ESR1 | P03372 | 1/20 | 0.60 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.60 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.60 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7649874 | 0.99 | MEN1 (0.61) | KCNH2CHRM2CHRM1CHRM4CHRM3 | |
| SCHEMBL8573019 | 0.83 | KEAP1 (0.52) | KCNH2CHRM2CHRM1CHRM4CHRM3 | |
| SCHEMBL717693 | 0.80 | CHRM2 (0.58) | KCNH2CHRM2CHRM1CHRM4CHRM3 | |
| SCHEMBL8470404 | 0.77 | CHRM2 (0.69) | KCNH2CHRM2CHRM1CHRM4CHRM3 | |
| Hydrochloric Acid SCHEMBL9474056 | 0.76 | MEN1 (0.70) | KCNH2CHRM2CHRM1CHRM4CHRM3 | |
| SCHEMBL8523994 | 0.76 | CHRM2 (0.68) | KCNH2CHRM2CHRM1CHRM4CHRM3 | |
| SCHEMBL4661231 | 0.75 | CHRM2 (0.58) | KCNH2CHRM2CHRM1CHRM4CHRM3 | |
| Aroxybutynin SCHEMBL25880 | 0.75 | CHRM2 (1.00) | KCNH2CHRM2CHRM1CHRM4CHRM3 | |
| Esoxybutynin SCHEMBL290373 | 0.75 | CHRM2 (1.00) | KCNH2CHRM2CHRM1CHRM4CHRM3 | |
| Oxybutynin SCHEMBL2992 | 0.75 | CHRM2 (1.00) | KCNH2CHRM2CHRM1CHRM4CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200246292-A1 | PHARMACEUTICAL COMPOSITIONS AND THE TREATMENT OF OVERACTIVE BLADDER | VELICEPT THERAPEUTICS, INC. (US) | 2020-08-06 | — | — | US | disclosed |
| US-10668034-B2 | Pharmaceutical compositions and the treatment of overactive bladder | VELICEPT THERAPEUTCIS, INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-10350182-B2 | Pharmaceutical compositions and the treatment of overactive bladder | VELICEPT THERAPEUTICS, INC. (US) | 2019-07-16 | — | — | US | disclosed |
| US-20180147169-A1 | PHARMACEUTICAL COMPOSITIONS AND THE TREATMENT OF OVERACTIVE BLADDER | B3AR THERAPEUTICS, INC. | 2018-05-31 | — | — | US | disclosed |
| US-9907767-B2 | Pharmaceutical compositions and the treatment of overactive bladder | VELICEPT THERAPEUTICS, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| US-20170151199-A1 | PHARMACEUTICAL COMPOSITIONS AND THE TREATMENT OF OVERACTIVE BLADDER | B3AR THERAPEUTICS, INC. | 2017-06-01 | — | — | US | disclosed |
| US-9522129-B2 | Pharmaceutical Combination | VELICEPT THERAPEUTICS, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| WO-2016004056-A1 | PHARMACEUTICAL COMBINATIONS | VELICEPT THERAPEUTICS, INC. (US) | 2016-01-07 | — | — | WO | disclosed |
| US-8642661-B2 | Pharmaceutical combinations of beta-3 adrenergic receptor agonists and muscarinic receptor antagonists | ALTHERX, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130172277-A1 | PHARMACEUTICAL COMBINATION | ALTHERX, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| EP-2600859-A1 | COMBINATIONS OF BETA - 3 ADRENERGIC RECEPTOR AGONISTS AND MUSCARINIC RECEPTOR ANTAGONISTS FOR TREATING OVERACTIVE BLADDER | Altherx Inc. (US) | 2013-06-12 | — | — | EP | disclosed |
| US-20120035118-A1 | PHARMACEUTICAL COMBINATIONS | ALTHERX, INC. (US) | 2012-02-09 | — | — | US | disclosed |
| WO-2012018773-A1 | COMBINATIONS OF BETA - 3 ADRENERGIC RECEPTOR AGONISTS AND MUSCARINIC RECEPTOR ANTAGONISTS FOR TREATING OVERACTIVE BLADDER | ALTHERX, INC. (US) | 2012-02-09 | — | — | WO | disclosed |
| EP-1383730-A2 | ANTICHOLINERGIC COMPOUNDS AND METHODS OF USE | Aryx Therapeutics (US) | 2004-01-28 | — | — | EP | disclosed |
| WO-2002096855-A2 | ANTICHOLINERGIC COMPOUNDS AND METHODS OF USE | ARYX THERAPEUTICS (US) | 2002-12-05 | — | — | WO | disclosed |
| US-20020169208-A1 | Novel anticholinergic compounds and methods of use | ARYX THERAPEUTICS | 2002-11-14 | — | — | US | disclosed |
| EP-1191930-A2 | METHODS FOR TREATMENT OF ASTHMA USING S-OXYBUTYNIN | Sepracor Inc. (US) | 2002-04-03 | — | — | EP | disclosed |
| US-6294582-B1 | THERAPY OF REVERSIBLE OBSTRUCTIVE PULMONARY DISEASE BY ADMINISTERING OPTICALLY PURE S-OXYBUTYNIN OR ITS SALT | SEPRACOR INC. | 2001-09-25 | — | — | US | disclosed |
| WO-2000071108-A2 | METHODS FOR TREATMENT OF ASTHMA USING S-OXYBUTYNIN | SEPRACOR INC. (US) | 2000-11-30 | — | — | WO | disclosed |
| WO-1998001125-A2 | DEXTROROTATORY ISOMERS OF OXYBUTYNIN AND DESETHYLOXYBUTYNIN IN THE TREATMENT OF GASTROINTESTINAL HYPERACTIVITY | SEPRACOR, INC. (US) | 1998-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172277-A1 | PHARMACEUTICAL COMBINATION | ADRB3, ADRB2, ADRB1 | KCNH2 972/4885CHRM2 16/4885CHRM1 49/4885 |
| US-20170151199-A1 | PHARMACEUTICAL COMPOSITIONS AND THE TREATMENT OF OVERACTIVE BLADDER | ADRB3, ADRA2B, ADRB1 | KCNH2 901/4885CHRM2 14/4885CHRM1 35/4885 |
| US-10350182-B2 | Pharmaceutical compositions and the treatment of overactive bladder | ADRB3, ADRA2B, ADRB1 | KCNH2 961/4885CHRM2 16/4885CHRM1 38/4885 |
| US-20120035118-A1 | PHARMACEUTICAL COMBINATIONS | ADRB3, ADRB2, ADRA2B | KCNH2 1349/4885CHRM2 22/4885CHRM1 76/4885 |
| US-20200246292-A1 | PHARMACEUTICAL COMPOSITIONS AND THE TREATMENT OF OVERACTIVE BLADDER | ADRB3, ADRA2B, ADRB1 | KCNH2 961/4885CHRM2 16/4885CHRM1 38/4885 |
| US-10668034-B2 | Pharmaceutical compositions and the treatment of overactive bladder | ADRB3, ADRA2B, ADRB1 | KCNH2 961/4885CHRM2 16/4885CHRM1 38/4885 |
| US-20020169208-A1 | Novel anticholinergic compounds and methods of use | CHRM3, CHRM5, CHRM2 | KCNH2 1044/4885CHRM2 3/4885CHRM1 9/4885 |
| US-20180147169-A1 | PHARMACEUTICAL COMPOSITIONS AND THE TREATMENT OF OVERACTIVE BLADDER | ADRB3, ADRA2B, ADRB1 | KCNH2 961/4885CHRM2 16/4885CHRM1 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.